PMS-BORTEZOMIB
Active Ingredient: BORTEZOMIB (BORTEZOMIB MANNITOL BORONIC ESTER)
Product Overview
About PMS-BORTEZOMIB
PMS-BORTEZOMIB is a prescription medication containing the active ingredient BORTEZOMIB (BORTEZOMIB MANNITOL BORONIC ESTER), used in the treatment of multiple myeloma and mantle cell lymphoma.
Key Benefits & Uses
- Treatment of multiple myeloma, including relapsed multiple myeloma and mantle cell lymphoma.
- Indicated for patients who have received at least one prior therapy.
- May be used in combination with other medications or as a single agent.
Active Ingredient & Action
BORTEZOMIB (BORTEZOMIB MANNITOL BORONIC ESTER) is a proteasome inhibitor that works by blocking the action of proteasomes, which are complexes within cells that break down proteins. By inhibiting proteasomes, BORTEZOMIB can induce apoptosis (cell death) in cancer cells, leading to a reduction in tumor size and symptoms.
Important Notes
PMS-BORTEZOMIB is available in injectable form and should be administered by a healthcare professional. Patients should be closely monitored for signs of infusion reactions, neutropenia, thrombocytopenia, and other potential side effects. It is essential to follow the recommended dosing schedule and to report any concerns or changes in health to a healthcare provider.
Visitor ratings
Help others by rating how useful this product page is.
No ratings yet — be the first.
